Iberdomide with dexamethasone: a new backbone for myeloma treatment?

Despite notable improvements in the treatment of multiple myeloma, leading to unprecedented overall survival rates, a substantial proportion of patients continue to relapse, and novel treatments continue to be needed. In addition, patients who show disease progression with proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies (triple-class exposed) remain a challenge, due to poor survival and an absence of standard of care available worldwide.